Free Access
Neuroepidemiology 2008;30:45–50
(DOI:10.1159/000115749)

Anti-Inflammatory Agents and Cognitive Decline in a Bi-Racial Population

Grodstein F.a, c, f · Skarupski K.A.a, c · Bienias J.L.a, c · Wilson R.S.b, d, e · Bennett D.A.b, d · Evans D.A.a, c
aRush Institute for Healthy Aging, bRush Alzheimer’s Disease Center, Departments of cInternal Medicine, dNeurological Sciences, and ePsychology, Rush University Medical Center, Chicago, Ill., fChanning Lab, Department of Medicine, Brigham and Women’s Hospital, Harvard Medical School, Boston, Mass., USA
email Corresponding Author


 goto top of outline Key Words

  • Chicago Health and Aging Project
  • Nonsteroidal anti-inflammatory drugs
  • Cognitive function

 goto top of outline Abstract

In a prospective study among 4,409 subjects aged 65+ years, we assessed the relation of nonsteroidal anti-inflammatory agents (NSAIDs) to cognition. The main outcome was decline in global cognitive function, determined by average performance across four cognitive tests, over up to four interviews. We found similar rates of cognitive decline among recent users of aspirin and of other NSAIDs (largely ibuprofen) compared to those who did not use these NSAIDs. For lifetime duration of aspirin use, we failed to find an association with cognitive decline. However, for other NSAIDs, increasing duration of lifetime use was related to slower rates of cognitive decline, relative to no use of other NSAIDs (5+ years vs. no use: mean difference = 0.12; p trend = 0.03). Overall, we found no relation between regular aspirin use and cognitive decline, but long-term use of ibuprofen may be related to decreased rates of cognitive decline in older persons.

Copyright © 2008 S. Karger AG, Basel


 goto top of outline References
  1. McGeer PL, Rogers J, McGeer EG: Inflammation, anti-inflammatory agents and Alzheimer disease, the last 12 years. J Alzheimers Dis 2006;9(3 suppl):271–276.
  2. ADAPT Research Group: Naproxen and celecoxib do not prevent AD in early results of a randomized controlled trial. Neurology 2007;68:1800–1808.
  3. Chen P, Ratcliff G, Belle SH, Cauley JA, DeKosky ST, Ganguli M: Patterns of cognitive decline in presymptomatic Alzheimer disease: a prospective community study. Arch Gen Psychiatry 2001;58:853–858.
  4. Kang JH, Cook NR, Manson J, Buring JE, Grodstein F: Low dose aspirin and cognitive function in the women’s health study cognitive cohort. BMJ 2007;334:987.
  5. De Craen AJ, Gussekloo J, Vrijsen B, Westendorp RG: Meta-analysis of anti-inflammatory drug use and risk of dementia. Am J Epidemiol 2005;161:114–120.
  6. Albert MS, Smith LA, Scherr PA, et al: Use of brief cognitive tests to identify individuals in the community with clinically-diagnosed Alzheimer’s disease. Internatl J Neurosci 1991;57:167–178.
  7. Scherr PA, Albert MS, Funkenstein HH, et al: Correlates of cognitive function in an elderly community population. Am J Epidemiol 1988;128:1084–1010.
  8. Folstein MF, Folstein SE, McHugh PR: ‘Mini-mental state’. A practical method for grading the cognitive state of patients for the clinician. J Psych Res 1975;12:189–198.
  9. Smith A: Symbol Digit Modalities Test Manual – Revised. Los Angeles, Western Psychological, 1984.
  10. Diggle PJ, Liang J-Y, Zeger SL: Analysis of Longitudinal Data. Oxford, Oxford University Press, 1994.
  11. Jonker C, Comijs HC, Smits JH: Does aspirin or other NSAIDs reduce the risk of cognitive decline in elderly persons? Results from a population-based study. Neurobiol Aging 2003;24:583–588.
  12. Sturmer T, Glynn RJ, Field TS, Taylor JO, Hennekens CH: Aspirin use and cognitive function in the elderly. Am J Epidemiol 1996;143:683–691.
  13. Kang JH, Grodstein F: Regular use of non-steroidal anti-inflammatory drugs and cognitive function in aging women. Neurology 2003;60:1591–1597.

    External Resources

  14. Akiyama H, Barger S, Barnum S, et al: Inflammation and Alzheimer’s disease. Neurobiol Aging 2000;21:383–421.
  15. Neuroinflammation Working Group: Inflammation and Alzheimer disease. Neurobiol Aging 2000;21:383–421.
  16. Klegeris A, McGeer PL: Non-steroidal anti-inflammatory drugs and other anti-inflammatory agents in the treatment of neurodegenerative disease. Curr Alzheimer Res 2005;2:355–365.
  17. Weggen S, Eriksen JL, Das P, et al: A subset of NSAIDs lower amyloidogenic Abeta42 independently of cyclooxygenase activity. Nature 2001;414:212–216.
  18. Steering Committee of the Physicians’ Health Study Research Group: Final report on the aspirin component of the ongoing Physicians’ Health Study. N Engl J Med 1989;321:129–135.
  19. Howard PA, Delafontaine P: Non-steroidal anti-inflammatory drugs and cardiovascular risk. J Am Coll Cardiol 2004;43:519–525.

 goto top of outline Author Contacts

Dr. Francine Grodstein
Channing Lab
181 Longwood Ave
Boston, MA 02115 (USA)
Tel. +1 617 525 2279, Fax +1 617 525 2008, E-Mail fgrodstein@partners.org


 goto top of outline Article Information

Received: July 11, 2007
Accepted: November 21, 2007
Published online: February 7, 2008
Number of Print Pages : 6
Number of Figures : 0, Number of Tables : 3, Number of References : 19


 goto top of outline Publication Details

Neuroepidemiology

Vol. 30, No. 1, Year 2008 (Cover Date: March 2008)

Journal Editor: Feigin, V.L. (Auckland)
ISSN: 0251–5350 (Print), eISSN: 1423–0208 (Online)

For additional information: http://www.karger.com/NED


Copyright / Drug Dosage / Disclaimer

Copyright: All rights reserved. No part of this publication may be translated into other languages, reproduced or utilized in any form or by any means, electronic or mechanical, including photocopying, recording, microcopying, or by any information storage and retrieval system, without permission in writing from the publisher or, in the case of photocopying, direct payment of a specified fee to the Copyright Clearance Center.
Drug Dosage: The authors and the publisher have exerted every effort to ensure that drug selection and dosage set forth in this text are in accord with current recommendations and practice at the time of publication. However, in view of ongoing research, changes in goverment regulations, and the constant flow of information relating to drug therapy and drug reactions, the reader is urged to check the package insert for each drug for any changes in indications and dosage and for added warnings and precautions. This is particularly important when the recommended agent is a new and/or infrequently employed drug.
Disclaimer: The statements, opinions and data contained in this publication are solely those of the individual authors and contributors and not of the publishers and the editor(s). The appearance of advertisements or/and product references in the publication is not a warranty, endorsement, or approval of the products or services advertised or of their effectiveness, quality or safety. The publisher and the editor(s) disclaim responsibility for any injury to persons or property resulting from any ideas, methods, instructions or products referred to in the content or advertisements.